Skip to main content

Table 1 Clinical characteristics of patients receiving GEM monotherapy.

From: Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer

Number of patients 35
Age (y) Mean ± SD (Range) 61.3 ± 8.5 (46–77)
Gender Male:Female 16: 19
Location Head: Body/tail 7: 28
Follow-up time from commencement of GEM monotherapy (mo)
  Median (Range) 7.7 (3.0–21.4)
Number of courses of GEM monotherapy
  Mean ± SD (Range) 5.9 ± 4.0 (2–16)
GEM efficacy Effective*: Non-effective 12: 23
  1. GEM, gemcitabine
  2. *Effective, partial response by imaging study or stable disease by imaging study with 50% or more decrease in tumor markers compared to pretreatment values